Maha FDA Begins Probe On Ambiguous Stickering & Mislabelling On Glenmark’s Hypertension Drug Telma

Mumbai: The Nashik Division of the Maharashtra Food and Drug Administration (FDA) has launched an inquiry into stickering and mislabelling practices observed on Glenmark’s hypertension medication, Telma 40 and Telma 20 tab batches, produced in Sikkim.

This investigation comes amidst allegations of deceptive maximum retail price (MRP) stickers, suspected to be applied by distributors rather than at the manufacturing site. Activist Nadie Jauhri has raised alarm over the potential anti-competitive ramifications and unlawful trade practices, urging regulatory intervention.

Glenmark Pharmaceuticals Ltd faces scrutiny for potential collusion with distributors, as highlighted in a case pending before the Competition Commission of India (CCI). The Maharashtra FDA has been alerted to these irregularities by Jauhri, urging swift action to address the issue.

According to activist Nadie Jauhri, these practices raise serious concerns about potential violations of the Drugs and Cosmetics (D&C) Act, suggesting that such actions may be motivated by distributors’ pressures on pharmaceutical companies to comply with unfair trade practices. Jauhri has pointed out that Glenmark Pharmaceuticals Ltd might be compelled to agree to these practices to avoid disruption of sales and distribution operations.

Highlighting the broader implications of such practices, Jauhri referred to a case (number 68 of 2015) currently before the Competition Commission of India (CCI). This case exposes the potential anti-competitive behavior resulting from limitations and controls imposed on drug supplies in the market. Glenmark Pharmaceutical Ltd has been implicated for allegedly entering into anti-competitive arrangements with distributors, violating prohibitions outlined in Section 3(1) of the Act.

In light of these allegations, Jauhri has written to the Maharashtra FDA, urging the regulatory body to intervene and address the unlawful practices instigated by Glenmark’s distributors. The Maharashtra FDA Nashik Division has taken cognizance of the matter and initiated an investigation to ascertain the veracity of the allegations and take appropriate action to safeguard consumer interests and uphold regulatory standards.

Related Posts

  • Pharma
  • May 25, 2024
  • 64 views
NPPA Revises Ceiling Price Of Asthma Inhaler Drug Combination In Suo-Moto Correction

New Delhi: The National Pharmaceutical Pricing Authority (NPPA) has revised the ceiling price of asthma inhaler drug combination formoteral 6 mcg and budesonide 400 mcg dry power inhaler (DPI) under…

  • Pharma
  • May 25, 2024
  • 75 views
Students Will Not Be Able To Take Admission In Pharmacy Institutes With Fake Documents, Strict Monitoring

Jaipur: To provide quality education in pharmacy institutes, the central government has prepared to end the duplicate system. Strict action will be taken against fake students and teachers in newly opened…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

A Doctor diagnoses Mood of Voters in Delhi

A Doctor diagnoses Mood of Voters in Delhi

NPPA Revises Ceiling Price Of Asthma Inhaler Drug Combination In Suo-Moto Correction

NPPA Revises Ceiling Price Of Asthma Inhaler Drug Combination In Suo-Moto Correction

Students Will Not Be Able To Take Admission In Pharmacy Institutes With Fake Documents, Strict Monitoring

Students Will Not Be Able To Take Admission In Pharmacy Institutes With Fake Documents, Strict Monitoring

Tripura Police Seized Banned Cough Syrup Worth Rs 30 Lakh In Dhalai; One Arrested

Tripura Police Seized Banned Cough Syrup Worth Rs 30 Lakh In Dhalai; One Arrested

Ex-Pharmacy Council Registrar Gave Certificates To Ineligible Candidates?

Ex-Pharmacy Council Registrar Gave Certificates To Ineligible Candidates?

Experts Call For Ethical Standards, Patient Advocacy In Clinical Research

Experts Call For Ethical Standards, Patient Advocacy In Clinical Research